HomeBiotechnology

Biotechnology

Record-Setting Pace Cools Off after Fed Minutes

Record-Setting Pace Cools Off after Fed Minutes

August 20, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV – GLPG

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Galapagos NV – GLPG

August 19, 2020

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. – BMRN

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of BioMarin Pharmaceutical Inc. – BMRN

August 19, 2020

Gilead (GILD) Gets CRL From FDA for Rheumatoid Arthritis Drug

Gilead (GILD) Gets CRL From FDA for Rheumatoid Arthritis Drug

August 19, 2020

Syros (SYRS) in Focus: Stock Moves 7.9% Higher

Syros (SYRS) in Focus: Stock Moves 7.9% Higher

August 19, 2020

Agenus (AGEN) in Focus: Stock Moves 7.6% Higher

Agenus (AGEN) in Focus: Stock Moves 7.6% Higher

August 19, 2020

Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer

Fate Therapeutics Appoints Edward Dulac as Chief Financial Officer

August 19, 2020

BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

August 19, 2020

Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors

Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid Tumors

August 19, 2020

Gilead Expands Collaboration With Tango for Cancer Therapies

Gilead Expands Collaboration With Tango for Cancer Therapies

August 18, 2020

« 1 … 508 509 510 511 512 … 543 »